Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma

Trial Details

NCT ID
NCT06932861
Phase
EARLY_PHASE1
Sponsor
Xinxin Zhang
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • personalized neoantigen mRNA vaccine
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing;
  • Age ≥ 6 years;
  • Has residual tumor or minor disease progression following standard therapy, and has no available effective treatment option. (\*: Prior to vaccine …
  • Expected survival time greater than 6 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →